FDA Approved Products

6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.

Type:AllNDABLAANDA
Lifecycle:GrowthPeakLOE ApproachingPost-LOELaunchPre-Launch
Sort:Approval DateNameCompetitive Pressure↓
CARDURA XL
doxazosin mesylate
LOE Approaching
Viatris (2)
ORAL · TABLET, EXTENDED RELEASE
hypertensionthe signs+1
2005
NDA
30/100
CARMUSTINE
carmustine
Peak
Accord Biopharma
INTRAVENOUS · POWDER
glioblastomamyeloma+1
2022
NDA
30/100
CARNITOR
levocarnitine
LOE Approaching
Leadiant Biosciences
ORAL · SOLUTION
the treatment of primary systemic carnitine deficiency
1986
NDA
30/100
CARNITOR
levocarnitine
LOE Approaching
Leadiant Biosciences
ORAL · SOLUTION
the treatment of primary systemic carnitine deficiency
1985
NDA
30/100
CARNITOR
levocarnitine
LOE Approaching
Leadiant Biosciences
INJECTION · INJECTABLE
1992
NDA
30/100
CARNITOR SF
levocarnitine
LOE Approaching
Leadiant Biosciences
ORAL · SOLUTION
the treatment of primary systemic carnitine deficiency
1986
NDA
30/100
CARTROL
carteolol hydrochloride
LOE Approaching
AbbVie
ORAL · TABLET
hypertensionglaucoma
1988
NDA
30/100
CASODEX
bicalutamide
LOE Approaching
ANI Pharmaceuticals
ORAL · TABLET
1995
NDA
30/100
CASODEX
bicalutamide
LOE Approaching
AstraZeneca
ORAL · TABLET
2008
NDA
30/100
CASPORYN HC
neomycin and polymyxin b sulfates and hydrocortisone otic
LOE Approaching
R-Pharm US
OTIC · SUSPENSION/DROPS
1975
NDA
30/100
CASSIPA
buprenorphine hydrochloride; naloxone hydrochloride
Peak
Teva
SUBLINGUAL · FILM
2018
NDA
30/100
CATAFLAM
diclofenac potassium
LOE Approaching
Novartis
ORAL · TABLET
migraine
1993
NDA
30/100
CATAPRES
clonidine hydrochloride
LOE Approaching
Boehringer Ingelheim
ORAL · TABLET
the treatment of hypertensionhypertension
1974
NDA
30/100
CATAPRES-TTS-1
clonidine transdermal system
LOE Approaching
Lavipharm
TRANSDERMAL · SYSTEM
the treatment of hypertensionhypertension
1984
NDA
30/100
CATAPRES-TTS-2
clonidine transdermal system
LOE Approaching
Lavipharm
TRANSDERMAL · SYSTEM
the treatment of hypertensionhypertension
1984
NDA
30/100
CATAPRES-TTS-3
clonidine transdermal system
LOE Approaching
Lavipharm
TRANSDERMAL · SYSTEM
the treatment of hypertensionhypertension
1984
NDA
30/100
CAVERJECT
alprostadil
LOE Approaching
Pfizer
INJECTION · INJECTABLE
erectile dysfunction
1997
NDA
30/100
CAVERJECT
alprostadil
LOE Approaching
Pfizer
INJECTION · INJECTABLE
erectile dysfunction
1995
NDA
30/100
CAVERJECT IMPULSE
alprostadil
LOE Approaching
Pfizer
INJECTION · INJECTABLE
erectile dysfunction
2002
NDA
30/100
CAYSTON
aztreonam
LOE Approaching
Gilead Sciences
INHALATION · FOR SOLUTION
respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa
2010
NDA
30/100
CECLOR
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · CAPSULE
the treatment of the following infectionsHaemophilus influenzae+3
1979
NDA
30/100
CECLOR
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · FOR SUSPENSION
the treatment of the following infectionsHaemophilus influenzae+3
1979
NDA
30/100
CECLOR CD
cefaclor
LOE Approaching
Eli Lilly and Company
ORAL · TABLET, EXTENDED RELEASE
the treatment of the following infectionsHaemophilus influenzae+3
1996
NDA
30/100
CEDAX
ceftibuten dihydrate
LOE Approaching
ORAL · FOR SUSPENSION
individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see
1995
NDA
30/100
← PreviousPage 29 of 277Next →